ATYs306Q6fE

65
163. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial
fibrillation poorly reflect its temporal persistence: insights from 1,195 patients
continuously monitored with implantable devices. J Am Coll Cardiol.
2014;63:2840–8.
164. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L.
Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial
Fibrillation Project. Int J Cardiol. 2013;167:2682–7.
165. Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: state of the
art. Lancet. 2012;380:1509–19.
166. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S,
Schotten U, Rienstra M. Lone atrial fibrillation: does it exist? J Am Coll Cardiol.
2014;63:1715–23.
167. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology
of atrial fibrillation: relationships among clinical features, epidemiology, and
me-chanisms. Circ Res. 2014;114:1453–68.
168. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li
CH, Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter
ablation in patients with paroxysmal atrial fibrillation associated with dia-betes
mellitus or impaired fasting glucose. Am J Cardiol. 2010;106:1615–20.
169. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K, Lip GY,
Larsen TB. The impact of smoking on thromboembolism and mortality in patients
with incident atrial fibrillation: insights from the Danish Diet, Cancer, and Health
study. Chest. 2014;145:559–66.
170. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, Lip GY,
Larsen TB. Alcohol intake and prognosis of atrial fibrillation. Heart. 2013;99:1093–9.
171. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski
E, McGann CJ, Parker D, Brachmann J, Macleod RS, Marrouche NF. Association of
left atrial fibrosis detected by delayed-enhancement magnetic res-onance
imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll
Cardiol. 2011;57:831–8.
172. Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA, Coelho-Filho O,
McMullan CJ, Heydari B, Michaud GF, John RM, van der Geest R, Steigner ML,
Blankstein R, Jerosch-Herold M, Kwong RY. The incidence, pattern, and prognostic
value of left ventricular myocardial scar by late gadolinium enhancement in
patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2205–14.
173. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski
E, Burgon N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M,
Mahnkopf C, Herweg B, Daoud E, Wissner E, Bansmann P, Brachmann J.
Association of atrial tissue fibrosis identified by delayed enhancement MRI and
atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498–506.
174. Bonizzi P, Zeemering S, Karel JM, Di Marco LY, Uldry L, Van Zaen J, Vesin JM,
Schotten U. Systematic comparison of non-invasive measures for the assessment
of atrial fibrillation complexity: a step forward towards standardization of atrial
fibrillation electrogram analysis. Europace. 2014;17:318–25.
175. Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G,
Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns
H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch
E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbuchel H, Heinrich- Nols J,
Hidden-Lucet F, Hindricks G, Juul-Moller S, Kaab S, Kappenberger L, Kespohl S,
Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Munzel F, Nabauer M,
Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U,
Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U,
Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S,
Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S,
Ziegler A, Lip GY, Camm AJ. A road-map to improve the quality of atrial fibrillation
management: proceedings from the fifth Atrial Fibrillation Network/European
Heart Rhythm Association consensus conference. Europace. 2016;18:37–50.
176. Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E,
Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW,
Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kaab S, Maniadakis N, Martin S, Mont
L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R,
West A, Ziegler A, Kirchhof P. Expert consensus document: Defining the major
health modifiers causing atrial fibrillation: a roadmap to under-pin personalized
prevention and treatment. Nat Rev Cardiol. 2016;13:230–7.
177. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, Akhtar M,
Luderitz B. The impairment of health-related quality of life in patients with
intermittent atrial fibrillation: implications for the assessment of investigational
therapy. J Am Coll Cardiol. 2000;36:1303–9.
178. Sears SF, Serber ER, Alvarez LG, Schwartzman DS, Hoyt RH, Ujhelyi MR. Understanding
atrial symptom reports: objective versus subjective predictors. Pacing
Clin Electrophysiol. 2005;28:801–7.
179. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type
of atrial fibrillation. Rev Esp Cardiol. 2010;63:1402–9.
180. Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T,
Merioua I, Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, Silva-Cardoso J,
Zharinov O, Brette S, Neill JO, RealiseAF investigators. Symptoms, functional status
and quality of life in patients with controlled and uncontrolled atrial
fibrillation: data from the RealiseAF cross-sectional international registry. Heart.
2012;98:195–201.
181. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH, Pharmacological Intervention
in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control
on quality of life in patients with persistent atrial fibrillation. Results from a
prospective randomized study. Eur Heart J. 2003;24:1430–6.
182. Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in
eld-erly patients with atrial fibrillation: a systematic review of randomized and
nonran-domized trials. Clin Med Insights Cardiol. 2013;7:1–20.
183. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma
JH, Crijns HJ, Van Gelder IC, RACE Study Group. Effect of rate or rhythm control
on quality of life in persistent atrial fibrillation. Results from the Rate Con-trol
Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43:241–7.
184. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam
L, Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Austra-lian intervention
randomized control of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol.
2003;41:1697–702.
185. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL,
McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to as-sess
catheter ablation versus rate control in the management of persistent atrial
fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894–903.
186. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder
IC, Ellinor PT, Benjamin EJ. Symptoms and functional status of patients with atrial
fib-rillation: state of the art and future research opportunities. Circulation.
2012;125:2933–43.
187. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramirez P, Badia X. Validation of
the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial
fibrillation. Europace. 2010;12:364–70.
188 . Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR,
Wimmer AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation
Effect on QualiTy-of-Life (AFEQT) Questionnaire in patients with atrial
fibrillation. Circ Arrhythm Electrophysiol. 2011;4:15–25.
189. Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR,
Wimmer AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial
fibrillation: How much change is meaningful? Am Heart J. 2013;166: 381–7.e8.
190. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International
Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903–12.
191. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X.
Development and preliminary testing of the new five-level version of EQ-5D (EQ-
5D-5L). Qual Life Res. 2011;20:1727–36.
192. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G,
Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S,
Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome
parameters for trials in atrial fibrillation: executive sum-mary. Eur Heart J.
2007;28:2803–17.
193. Dorian P, Cvitkovic SS, Kerr CR, Crystal E, Gillis AM, Guerra PG, Mitchell LB, Roy
D, Skanes AC, Wyse DG. A novel, simple scale for assessing the symptom severity
of atrial fibrillation at the bedside: the CCS-SAF scale. Can J Cardiol. 2006;22:383–6.
194. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ,
Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European
coun-tries after the publication of the 2010 ESC Guidelines on atrial fibrillation:
primary results of the PREvention oF thromboemolic events—European Registry
in Atrial Fibrillation (PREFER in AF). Europace. 2014;16:6–14.
195. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z,
Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes
with European Society of Cardiology guideline-adherent antithrombo-tic
treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF
General Pilot Registry. Europace. 2015;17:1777–86.
196. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey
PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP, Outcomes Registry
for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investi-gators and
Patients. Association Between Atrial Fibrillation Symptoms, Quality of Life,
and Patient Outcomes: Results From the Outcomes Registry for Better In-formed
Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes.
2015;8:393–402.
197. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH,
Sinagra G, Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation:
clinical correlates, management, and outcomes in the EORP-AF Pilot General
Registry. Am J Med. 2015;128:509–518 e2.
198. Szymanski FM, Filipiak KJ, Karpinski G, Platek AE, Opolski G. Occurrence of poor
sleep quality in atrial fibrillation patients according to the EHRA score. Acta
Cardiol. 2014;69:291–6.
199. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The
European Heart Rhythm Association symptom classification for atrial fibrillation:
validation and improvement through a simple modification. Europace.
2014;16:965–72.
200. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P, ATRIUM investigators.
Management of atrial fibrillation by primary care physicians in
Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100:
897–905.
201. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A,
Lewalter T, Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the
German Competence NETwork on Atrial Fibrillation: Patient characteristics and
initial management. Europace. 2009;11:423–34.
202. von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M,
Baumert J, Ladwig KH. Depression in paroxysmal and persistent atrial fibrillation
patients: a cross-sectional comparison of patients enroled in two large clinical
trials. Europace. 2014;16:812–9.
203. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M,
Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P.
Aggressive risk factor reduction study for atrial fibrillation and implica-tions for
the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol.
2014;64:2222–31.
204. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer
MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect